AstraZeneca shares: should I buy now?

first_img Click here to claim your copy now — and we’ll tell you the name of this Top US Share… free of charge! Edward Sheldon, CFA | Thursday, 3rd December, 2020 | More on: AZN The last time I analysed AstraZeneca (LSE:AZN) shares was all the way back in April 2018. At the time, Neil Woodford had just sold the FTSE 100 pharmaceutical stock. I said, however, that it was worth holding on to.Holding AZN shares was certainly the right move. Since that article, AstraZeneca’s share price has risen from 5,400p to 7,800p – a gain of around 44%. At one point in July, the share price was above 10,000p.5G is here – and shares of this ‘sleeping giant’ could be a great way for you to potentially profit!According to one leading industry firm, the 5G boom could create a global industry worth US$12.3 TRILLION out of thin air…And if you click here we’ll show you something that could be key to unlocking 5G’s full potential…Would I buy AstraZeneca shares today though? Let’s take a look at the investment case.AstraZeneca: the investment caseIn today’s world, in which global populations are ageing and the burden of disease is increasing, I see AstraZeneca as well positioned for growth. Its areas of focus (Oncology; Cardiovascular, Renal and Metabolism; and Respiratory diseases) are all highly relevant today. And with a portfolio of speciality and primary care medicines, a global presence, and strength in the emerging markets, it looks well placed for success.Of course, I can’t write an article about AstraZeneca and not discuss its Covid-19 vaccine. News that the group has developed a vaccine, in conjunction with Oxford University, is certainly exciting. However, this may not be the game-changer that some investors were hoping for. This is due to the fact that AZN has promised not to profit from the vaccine during the pandemic. The company’s approach has been to treat the development of the vaccine as a response to a global public health emergency and not a commercial opportunity. This explains why the share price hasn’t surged higher recently.Revenue is climbingTurning to the financials, AstraZeneca’s top-line growth has picked up recently, after stagnating for several years. Revenue in 2019 was $24.38bn, up from $22.09bn in 2018.Looking ahead, City analysts forecast revenue of $26.43bn this year and $29.89bn next year, which is encouraging. Profits are also expected to rise. Last year, AZN’s net profit was $1.3bn. This year and next year, analysts forecast net profit of $5.3bn and $6.7bn respectively. This is all quite positive. Balance sheet issuesThere are some issues that concern me, however. One is the level of debt on the company’s balance sheet. At 30 September, this stood at $13.76bn. Total equity was $13.62bn. This debt-to-equity ratio is a little higher than I like to see.The second is the valuation. Currently, AZN’s P/E ratio is 25.5 using this year’s earnings forecast. It falls to 20.7 using next year’s forecast. These valuations are not outrageously high. But they probably don’t leave a lot of room for error.My view on AZN todayWeighing everything up, I continue to see AstraZeneca shares as a hold today.If I owned the shares (I don’t), I’d hold on to them. If I didn’t, I’d keep them on my watchlist for now with a view to buying at a slightly cheaper valuation.At the moment, I think there are probably better stocks to buy. Simply click below to discover how you can take advantage of this. Image source: Getty Images “This Stock Could Be Like Buying Amazon in 1997” AstraZeneca shares: should I buy now? Edward Sheldon has no position in any shares mentioned. The Motley Fool UK has no position in any of the shares mentioned. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.center_img I would like to receive emails from you about product information and offers from The Fool and its business partners. Each of these emails will provide a link to unsubscribe from future emails. More information about how The Fool collects, stores, and handles personal data is available in its Privacy Statement. I’m sure you’ll agree that’s quite the statement from Motley Fool Co-Founder Tom Gardner.But since our US analyst team first recommended shares in this unique tech stock back in 2016, the value has soared.What’s more, we firmly believe there’s still plenty of upside in its future. In fact, even throughout the current coronavirus crisis, its performance has been beating Wall St expectations.And right now, we’re giving you a chance to discover exactly what has got our analysts all fired up about this niche industry phenomenon, in our FREE special report, A Top US Share From The Motley Fool. Renowned stock-picker Mark Rogers and his analyst team at The Motley Fool UK have named 6 shares that they believe UK investors should consider buying NOW.So if you’re looking for more stock ideas to try and best position your portfolio today, then it might be a good day for you. Because we’re offering a full 33% off your first year of membership to our flagship share-tipping service, backed by our ‘no quibbles’ 30-day subscription fee refund guarantee. Enter Your Email Address See all posts by Edward Sheldon, CFA Our 6 ‘Best Buys Now’ Shareslast_img

Leave a Reply

Your email address will not be published. Required fields are marked *